Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 49.30
-1.70 (-3.33%)
At close: Dec 4, 2025
Navana Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 |
| Revenue | 9,520 | 8,843 | 6,898 | 5,706 | 4,759 | 3,607 | Upgrade
|
| Revenue Growth (YoY) | 28.58% | 28.19% | 20.89% | 19.91% | 31.95% | 14.53% | Upgrade
|
| Cost of Revenue | 5,404 | 4,965 | 3,770 | 3,110 | 2,599 | 1,993 | Upgrade
|
| Gross Profit | 4,116 | 3,878 | 3,128 | 2,596 | 2,160 | 1,614 | Upgrade
|
| Selling, General & Admin | 2,650 | 2,432 | 2,136 | 1,841 | 1,591 | 1,265 | Upgrade
|
| Operating Expenses | 2,650 | 2,432 | 2,136 | 1,841 | 1,591 | 1,265 | Upgrade
|
| Operating Income | 1,466 | 1,446 | 991.84 | 755.72 | 569.6 | 348.59 | Upgrade
|
| Interest Expense | -665.23 | -726.63 | -463.57 | -234.89 | -200.42 | -75.18 | Upgrade
|
| Interest & Investment Income | 1.4 | 1.07 | 1.47 | 5.84 | 5.58 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -47.02 | -54.08 | -25.18 | -33.38 | -93.98 | -2.52 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.13 | 6.15 | 11.39 | -1.91 | 27.64 | 30.47 | Upgrade
|
| EBT Excluding Unusual Items | 776.58 | 672.48 | 515.95 | 491.38 | 308.42 | 301.39 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -10.46 | -0.88 | -42.3 | 82.9 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.09 | -0.09 | 1.18 | - | 0.47 | 1.02 | Upgrade
|
| Pretax Income | 776.49 | 661.93 | 516.25 | 449.08 | 391.79 | 302.41 | Upgrade
|
| Income Tax Expense | 238.74 | 174.12 | 111.62 | 92.14 | 117.78 | 100.12 | Upgrade
|
| Net Income | 537.75 | 487.81 | 404.63 | 356.94 | 274 | 202.29 | Upgrade
|
| Net Income to Common | 537.75 | 487.81 | 404.63 | 356.94 | 274 | 202.29 | Upgrade
|
| Net Income Growth | 28.39% | 20.56% | 13.36% | 30.27% | 35.45% | 47.23% | Upgrade
|
| Shares Outstanding (Basic) | 108 | 107 | 107 | 99 | 80 | 80 | Upgrade
|
| Shares Outstanding (Diluted) | 108 | 107 | 107 | 99 | 80 | 80 | Upgrade
|
| Shares Change (YoY) | 0.56% | - | 8.05% | 23.91% | - | - | Upgrade
|
| EPS (Basic) | 5.00 | 4.54 | 3.77 | 3.59 | 3.42 | 2.52 | Upgrade
|
| EPS (Diluted) | 4.99 | 4.54 | 3.77 | 3.59 | 3.42 | 2.52 | Upgrade
|
| EPS Growth | 27.59% | 20.56% | 4.92% | 5.13% | 35.45% | 47.23% | Upgrade
|
| Free Cash Flow | 1,907 | 1,444 | -625.1 | -1,404 | -1,160 | -399 | Upgrade
|
| Free Cash Flow Per Share | 17.69 | 13.44 | -5.82 | -14.13 | -14.45 | -4.97 | Upgrade
|
| Dividend Per Share | 1.400 | 1.400 | 1.400 | 1.300 | 1.100 | - | Upgrade
|
| Dividend Growth | - | - | 7.69% | 18.18% | - | - | Upgrade
|
| Gross Margin | 43.23% | 43.85% | 45.34% | 45.50% | 45.39% | 44.75% | Upgrade
|
| Operating Margin | 15.40% | 16.35% | 14.38% | 13.24% | 11.97% | 9.66% | Upgrade
|
| Profit Margin | 5.65% | 5.52% | 5.87% | 6.25% | 5.76% | 5.61% | Upgrade
|
| Free Cash Flow Margin | 20.03% | 16.33% | -9.06% | -24.61% | -24.37% | -11.06% | Upgrade
|
| EBITDA | 1,744 | 1,715 | 1,163 | 966.13 | 675.37 | 397.71 | Upgrade
|
| EBITDA Margin | 18.32% | 19.39% | 16.86% | 16.93% | 14.19% | 11.03% | Upgrade
|
| D&A For EBITDA | 277.99 | 268.77 | 171.25 | 210.41 | 105.77 | 49.12 | Upgrade
|
| EBIT | 1,466 | 1,446 | 991.84 | 755.72 | 569.6 | 348.59 | Upgrade
|
| EBIT Margin | 15.40% | 16.35% | 14.38% | 13.24% | 11.97% | 9.66% | Upgrade
|
| Effective Tax Rate | 30.75% | 26.30% | 21.62% | 20.52% | 30.06% | 33.11% | Upgrade
|
| Advertising Expenses | - | 42.15 | 38.4 | 33.13 | 80.86 | 19.55 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.